Global Targeted Therapeutics Market Size to Reach USD 214.31 Billion in 2032 | Emergen Research
October 16, 2023 09:09 ET
|
Emergen Research
Vancouver, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Current Market Scenario (Market estimates) The global Targeted Therapeutics Market size was USD 93.75 Billion in 2020. Increasing prevalence of cancer,...
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
October 12, 2023 16:05 ET
|
Immuneering Corporation
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven...
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023 16:05 ET
|
Immuneering Corporation
- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and...
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
August 03, 2023 08:00 ET
|
Immunocore Holdings Limited
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore...
invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
June 19, 2023 08:30 ET
|
invIOs GmbH
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly inhibits tumor...
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
June 03, 2023 07:00 ET
|
Immunocore Holdings Limited
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...
Immunocore to present at upcoming investor conferences
June 01, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 June 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Companion Diagnostics Market to Expand at a CAGR of 9% during Forecast Period: TMR Study
April 21, 2023 08:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 21, 2023 (GLOBE NEWSWIRE) -- The global companion diagnostics market size stood at USD 5.24 Bn in 2020 and is estimated to reach USD 9.30 Bn by 2028. The...
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023 09:00 ET
|
Immuneering Corporation
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or...
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
April 18, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated...